Sponsored by
Impressive results for newly diagnosed GBM with a "stock" vaccine - this is not custom made for each patient but instead targets Survivin, which is overexpressed in over 95% of GBM patients. This is now in clinical trials for newly diagnosed GBM as well as children with progressive or relapsed brain tumors including GBM, AA, medulloblastoma, Ependymoma and others. For DIPG, the trial accepts non relapsed DIPG (After radiation).
CTIM-26. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA